Terms: = Endocrine gland cancer AND FLT4, FLT41, 2324, ENSG00000037280, P35916, VEGFR3, PCL AND Prognosis
22 results:
1. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line.
Szász Z; Enyedi KN; Takács A; Fekete N; Mező G; Kőhidai L; Lajkó E
Biomed Pharmacother; 2024 Apr; 173():116293. PubMed ID: 38430628
[TBL] [Abstract] [Full Text] [Related]
2. An integrated analysis identifies six molecular subtypes of pancreatic ductal adenocarcinoma revealing cellular and molecular landscape.
Li L; Shen L; Wu H; Li M; Chen L; Zhou Q; Ma J; Huai C; Zhou W; Wei M; Zhao M; Zhao X; Du H; Jiang B; Sun Y; Zhang N; Qin S; Xing T
Carcinogenesis; 2023 Dec; 44(10-11):726-740. PubMed ID: 37747815
[TBL] [Abstract] [Full Text] [Related]
3. The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review.
Brind'Amour A; Webb M; Parapini M; Sidéris L; Segedi M; Chung SW; Chartier-Plante S; Dubé P; Scudamore CH; Kim PTW
Clin Exp Metastasis; 2021 Apr; 38(2):187-196. PubMed ID: 33486670
[TBL] [Abstract] [Full Text] [Related]
4. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.
Sopo M; Anttila M; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Sallinen H
BMC Cancer; 2019 Jun; 19(1):584. PubMed ID: 31200683
[TBL] [Abstract] [Full Text] [Related]
5. Dendritic Polyglycerol-Derived Nano-Architectures as Delivery Platforms of Gemcitabine for Pancreatic cancer.
Ray P; Ferraro M; Haag R; Quadir M
Macromol Biosci; 2019 Jul; 19(7):e1900073. PubMed ID: 31183964
[TBL] [Abstract] [Full Text] [Related]
6. Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
Yang D; Tang Y; Fu H; Xu J; Hu Z; Zhang Y; Cai Q
Biochem Biophys Res Commun; 2018 Oct; 505(1):215-221. PubMed ID: 30243721
[TBL] [Abstract] [Full Text] [Related]
7. Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.
Berardi R; Torniai M; Partelli S; Rubini C; Pagliaretta S; Savini A; Polenta V; Santoni M; Giampieri R; Onorati S; Barucca F; Murrone A; Bianchi F; Falconi M
PLoS One; 2018; 13(5):e0197035. PubMed ID: 29787601
[TBL] [Abstract] [Full Text] [Related]
8. The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma.
Cooke SL; Ennis D; Evers L; Dowson S; Chan MY; Paul J; Hirschowitz L; Glasspool RM; Singh N; Bell S; Day E; Kochman A; Wilkinson N; Beer P; Martin S; Millan D; Biankin AV; McNeish IA;
Clin Cancer Res; 2017 Dec; 23(24):7633-7640. PubMed ID: 28954785
[No Abstract] [Full Text] [Related]
9. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy of lenvatinib in treating thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Pharmacother; 2016 Aug; 17(12):1683-91. PubMed ID: 27398740
[TBL] [Abstract] [Full Text] [Related]
11. FH535, a β-catenin pathway inhibitor, represses pancreatic cancer xenograft growth and angiogenesis.
Liu L; Zhi Q; Shen M; Gong FR; Zhou BP; Lian L; Shen B; Chen K; Duan W; Wu MY; Tao M; Li W
Oncotarget; 2016 Jul; 7(30):47145-47162. PubMed ID: 27323403
[TBL] [Abstract] [Full Text] [Related]
12. High levels of circulating CD34+/vegfr3+ lymphatic/vascular endothelial progenitor cells is correlated with lymph node metastasis in patients with epithelial ovarian cancer.
Qiu H; Cao L; Wang D; Xu H; Liang Z
J Obstet Gynaecol Res; 2013 Jul; 39(7):1268-75. PubMed ID: 23803010
[TBL] [Abstract] [Full Text] [Related]
13. Papillary thyroid carcinoma involving cervical neck lymph nodes: correlations with lymphangiogenesis and ultrasound features.
Choi Y; Park KJ; Ryu S; Kim DH; Yun J; Kang DK; Chun M
Endocr J; 2012; 59(10):941-8. PubMed ID: 22785182
[TBL] [Abstract] [Full Text] [Related]
14. Clinical significance of VEGFR-2 and VEGFR-3 expression in ovarian cancer patients.
Klasa-Mazurkiewicz D; Jarząb M; Milczek T; Lipińska B; Emerich J
Pol J Pathol; 2011; 62(1):31-40. PubMed ID: 21574104
[TBL] [Abstract] [Full Text] [Related]
15. Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice.
Sallinen H; Anttila M; Gröhn O; Koponen J; Hämäläinen K; Kholova I; Kosma VM; Heinonen S; Alitalo K; Ylä-Herttuala S
Cancer Gene Ther; 2011 Feb; 18(2):100-9. PubMed ID: 20865022
[TBL] [Abstract] [Full Text] [Related]
16. Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer.
Doi Y; Yashiro M; Yamada N; Amano R; Ohira G; Komoto M; Noda S; Kashiwagi S; Kato Y; Fuyuhiro Y; Hirakawa K
Cancer Sci; 2010 Jun; 101(6):1529-35. PubMed ID: 20367641
[TBL] [Abstract] [Full Text] [Related]
17. Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas.
Näyhä V; Stenbäck F
APMIS; 2008 Feb; 116(2):107-17. PubMed ID: 18321361
[TBL] [Abstract] [Full Text] [Related]
18. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.
Von Marschall Z; Scholz A; Stacker SA; Achen MG; Jackson DG; Alves F; Schirner M; Haberey M; Thierauch KH; Wiedenmann B; Rosewicz S
Int J Oncol; 2005 Sep; 27(3):669-79. PubMed ID: 16077915
[TBL] [Abstract] [Full Text] [Related]
19. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.
Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR
Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449
[TBL] [Abstract] [Full Text] [Related]
20. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma.
Nishida N; Yano H; Komai K; Nishida T; Kamura T; Kojiro M
Cancer; 2004 Sep; 101(6):1364-74. PubMed ID: 15368324
[TBL] [Abstract] [Full Text] [Related]
[Next]
